Determinants of Low Bone Turnover in Type 2 Diabetes—the Role of PTH

Janina Vavanikunnel¹ · Lilian Sewing¹ · Maria Triantafyllidou² · Anna Steighardt² · Sandra Baumann¹ · Andrea Egger¹ · Leticia Grize³,4 · Barbara Felix⁵ · Marius Kraenzlin⁶ · Christoph Henzen² · Christian Meier¹,6

Received: 11 February 2022 / Accepted: 3 September 2022 / Published online: 3 October 2022

© The Author(s) 2022

Abstract
Determinants of low bone turnover in type 2 diabetes (T2DM) are poorly understood. To investigate the relationship between markers of bone turnover, glycaemic control, disease duration and calcitropic hormones in T2DM we assessed baseline biochemical data from the DiabOS Study, a prospective multicenter observational cohort study. In a cross-sectional study-design data from 110 postmenopausal women and men aged 50–75 years diagnosed with T2DM for at least 3 years and 92 non-diabetic controls were evaluated. Biochemical markers of bone formation (N-terminal propeptide of type I procollagen [PINP]), bone-specific alkaline phosphatase [BAP]) and resorption (C-terminal cross-linking telopeptide of type I collagen [CTX]), measures of calcium homeostasis (intact parathormone [iPTH], 25-Hydroxyvitamin D, calcium, magnesium) and glycaemic control were assessed. After adjustment for age, gender and body mass index (BMI), patients with T2DM had lower serum levels of PINP (p < 0.001), CTX (p < 0.001), iPTH (p = 0.03) and magnesium (p < 0.001) compared to controls. Serum calcium, creatinine, 25-Hydroxyvitamin D and sclerostin did not differ between both groups. In multivariate linear regression analyses only serum iPTH remained an independent determinant of bone turnover markers in T2DM (PINP: p = 0.02; CTX: p < 0.001 and BAP: p < 0.01), whereas glycated haemoglobin (HbA1c), disease duration, age and BMI were not associated with bone turnover. In conclusion low bone turnover in T2DM is associated with low iPTH. The underlying mechanism remains to be elucidated.

Keywords Diabetes · Hypoparathyroidism · Bone turnover

Introduction
Type 2 diabetes mellitus (T2DM) has been established to be a state of low bone turnover [1–6]. Histological data indicate significant reductions in indices of bone resorption [2] as well as reduced dynamic indices of bone formation [2, 3]. This has been confirmed in various clinical studies assessing biochemical markers of bone turnover [2, 3, 7–10]. Based on a meta-analysis Hygum et al. found that both markers of bone formation (N-terminal propeptide of type I procollagen (PINP) and osteocalcin (OC)) and markers of bone resorption (C-terminal cross-linking telopeptide of type I collagen (CTX) and isoform 5b of tartrate resistant acid phosphatase (TRACP5b)) were decreased in T2DM [11].

Type 2 diabetes is associated with an increased risk for fragility fractures [12–15]; however, the mechanisms accounting for bone fragility remain to be elucidated. Since patients with T2DM have equivalent or higher bone mineral density (BMD) as compared to non-diabetic controls
Elevated plasma glucose was associated with decreased levels of CTX and TRAP5b have been found to correlate with low levels of parathormone (PTH) but potential implications of serum magnesium levels were not addressed [21, 22]. An impaired PTH secretion caused by a calcium-sensing defect or secondary to chronic hypomagnesemia has been discussed in T2DM [23] and an increased prevalence of hypomagnesemia has been identified in T2DM, especially in patients with poor glycaemic control, with a longer disease duration and chronic vascular complications [24, 25].

However, the chronic hyperglycaemic state itself may decrease bone turnover [26]. Elevated plasma glucose was associated with decreased levels of CTX, P1NP and OC [27] in patients with diabetes and negative correlations between levels of glycated haemoglobin (HbA1c) and OC and CTX have been observed [16, 28]. Furthermore, serum levels of sclerostin, a negative regulator of osteoblastogenesis, were elevated in T2DM [10, 29] and have been shown to correlate with the occurrence of fragility fractures [30, 31].

Further insight into the determinants of low bone turnover may improve the detection and treatment of patients with diabetic bone disease: To our knowledge this is the first study to comprehensively evaluate potential regulators of low bone turnover in type 2 diabetes including iPTH, magnesium, glycaemic control, disease duration and sclerostin levels.

Methods

Study Population and Design

Data were obtained from the DiabOS Study, a prospective multicenter observational cohort study evaluating skeletal health in T2DM and non-diabetic controls. The study was conducted according to the ethical guidelines of the Declaration of Helsinki, the International Conference on Harmonization guidelines on good clinical practice and national legal and regulatory requirements and was approved by the local ethical committee. Written informed consent was obtained from all patients and non-diabetic controls.

Postmenopausal women and men (aged 50–75 years, body mass index [BMI] 18–37 kg/m²) and postmenopausal female and male non-diabetic controls were recruited at University Hospital Basel, Kantonsspital Luzern and Kantonsspital Baselland, Switzerland and via press advertisement. Patients with diabetes were enrolled if they had a documented diagnosis of type 2 diabetes for at least 3 years and if they were treated with oral antidiabetics or insulin. For the DiabOS Study patients and non-diabetic controls were divided into groups with (T2DMFx, CoFx) and without fragility fractures (T2DM and Co). Participants needed to be able to move without assistance.

Exclusion criteria comprised any medical or psychiatric condition which would preclude the participants from adhering to the protocol, idiopathic or premenopausal osteoporosis, previous treatment with osteoporosis medication or intake of drugs known to affect bone metabolism (e.g. steroids, thiazolidinediones) within 6 months prior to enrolment or medical conditions known to affect bone health (e.g. metabolic bone disease such as primary hyperparathyroidism or Paget’s disease, metastatic bone disease, thyrotoxicosis, hypercortisolism).

Within the DiabOS study participants were followed at yearly intervals over 3 years (clinical, biochemical and densitometric assessment). During a standardized interview data on current medical treatment and presence of microvascular diabetic complications (retinopathy, neuropathy, nephropathy defined as microalbuminuria) were obtained and supplemented by medical records when appropriate. Daily calcium intake was calculated based on a semiquantitative in-house food frequency questionnaire.

For the purpose of this cross-sectional study, the baseline biochemical data of the first 202 consecutive participants without fragility fractures recruited for DiabOS were evaluated including 110 patients with T2DM (median disease duration, 13.5 years) and 92 non-diabetic controls.

Biochemical Assessment

Fasting blood samples were drawn between 08:00 and 11:00 a.m. and fresh serum aliquots were stored at −80 °C until analysis. Samples were analysed for HbA1c (Alere, Afinion), fasting glucose and insulin with the automated Elecsys® Insulin assay on a cobas e 411 analyzer (Roche Diagnostics International, Rotkreuz, Switzerland).
Calcium, phosphate, magnesium and creatinine were analysed by standard method on an autoanalyzer (Hitachi System 704 analyzer; Roche Diagnostics International, Rotkreuz, Switzerland). Serum bone-specific alkaline phosphatase (BAP) was determined by an ELISA assay (MicroVueBAP, Quidel, San Diego/USA); the intra- and interassay variations were < 5.8% and 7.6%, respectively. The parameters CTX, PINP, 25-Hydroxyvitamin D (25OH vitamin D, Vitamin D total) and intact parathyroid hormone (iPTH) were measured in serum with Eclecsys® assays on the automated analyzer cobas e 411 (Roche Diagnostics International, Rotkreuz, Switzerland). The intra- and interassay variations were 2.0 and 8.4% for CTX, 1.2 and 3.3% for PINP, 2.2 and 10.7% for 25OH vitamin D and 1.2 and 2.0% for iPTH, respectively. The expected values for the iPTH assay were ≤ 7 and ≤ 10%, respectively (Biomedica, Vienna/Austria).

Urinary albumin was measured by immunoturbidimetry [MicroAlb SeraPak (Bayer, Tarrytown, NY) on Cobas Mira Plus (Roche Diagnostics International, Rotkreuz, Switzerland)]. The mean intra- and inter-assay variations were 4.5 and 7.6%, respectively. Urine creatinine and urine phosphate were measured on an automated analyzer (Beckman Coulter® AU analyzer). Renal tubular reabsorption of phosphate (Tmp/GFR in mmol/l of glomerular filtrate) was calculated using the following equation according to Payne RB: 

\[
\text{TRP} = \text{TmP/GFR} = \text{TR} \times \text{serum phosphate}.
\]

TRP (fractional tubular reabsorption of phosphate) = 1 – (Serum creatinine x Urine phosphate/Urine creatinine x Serum phosphate) [32].

A multivariate regression analysis was done for PINP, CTX and BAP. Furthermore, correlation analyses were calculated between iPTH and HbA1c, disease duration, serum bone turnover markers, urinary albumin/creatinine ratio, magnesium and vascular complications. Pearson correlation coefficients were calculated for correlation with continuous parameters, and Spearman’s correlation coefficients were calculated for correlations with categorical and continuous parameters.

The software Statistical Analysis System 9.4 (SAS Institute, Cary NC, USA) was used for the analysis. The level for statistical significance was set to an alpha < 0.05.

Results

Patient Characteristics

In this cross-sectional case–control study we included 110 patients with T2DM and 92 non-diabetic controls. Patients with T2DM were predominantly male (T2DM male 71.82%, CO male 25%, p < 0.001), were older (T2DM 63.7 ± 6.0 yrs, CO 60.5 ± 6.3 yrs, p < 0.001) and had a significantly higher BMI (T2DM 29.8 ± 4.3 kg/m², CO 24.9 ± 4.5 kg/m², p < 0.001) and more comorbidities (T2DM n = 106/110, 96.4%, CO n = 74/92, 80.4%, p < 0.001) as compared to non-diabetic controls.

Median diabetes duration was 13.5 years (IQR 8–20 years). Diabetes was moderately to well controlled with a mean HbA1c of 7.5 ± 1.2%. 64 patients (58.2%) were treated with insulin and in 76 patients (69.1%) microvascular complications were present. 85.4% of the T2DM patients were on Metformin treatment. 23.6% were taking SLGT-2 inhibitors. (Table 1).

Biochemical Characteristics

Raw data distribution of PINP, CTX, iPTH and magnesium for T2DM and non-diabetic controls is shown in Figs. 1, 2 and3. The results after adjustment for age, gender and BMI are presented in Table 2: Adjusted mean levels of PINP, CTX and iPTH were lower in T2DM patients with T2DM who had significantly lower serum levels of PINP (T2DM: 39.61 ng/ml, 95%CI 35.37–43.85; CO: 57.38 ng/ml, 95%CI 52.57–62.18; p < 0.001) and CTX (T2DM: 29.8 ± 4.3 kg/m², CO 24.9 ± 4.5 kg/m², p < 0.001) as compared to non-diabetic controls. BAP levels did not significantly differ between the groups (T2DM: 25.85 ± 6.23, CO: 25.75 ± 6.18; p = 0.18). Serum iPTH (T2DM: 0.29 ng/ml, 95%CI 0.26–0.32; CO: 0.39–0.46; p < 0.001) as compared to non-diabetic controls. BAP levels did not significantly differ between the groups (T2DM: 14.73 µg/l, 95%CI 13.24–16.23; CO:16.45 µg/l, 95%CI 14.75–18.14; p = 0.18). Serum iPTH (T2DM: 0.81 mmol/L, 95%CI 0.79–0.83; CO: 0.89 mmol/L, 95%CI 0.86–0.92; p < 0.001) were significantly lower in T2DM. For

Statistical Analysis

Descriptive statistics of categorical parameters were summarized as counts and percentages (e.g. gender, comorbidities, insulin treatment, neuropathy, retinopathy, nephropathy). Chi-square test or the Fisher’s exact test were used to compare the T2DM and control groups. Continuous parameters were expressed as means and standard deviations (SD) or medians and interquartile range (IQR). Mann–Whitney U test was used to compare the two groups. The means were adjusted for age, gender and BMI. Serum magnesium levels were additionally adjusted for thiazide and proton pump inhibitor use. When adjusting the means generalized linear regression models were used and the respective adjusted means were extracted.
To adjust for potential confounders, we performed additional analyses. Serum magnesium levels were significantly higher in the diabetic group compared to non-diabetic controls.

Serum calcium, creatinine, 25OH vitamin D, nutritional calcium intake and Vitamin D supplementation did not differ between the groups after adjustment for age, gender and BMI.

Unadjusted serum sclerostin levels were higher in T2DM compared to the non-diabetic population. However, this effect did not remain significant after adjustment for age, gender and BMI (T2DM: 39.1 mmol/L, 95% CI 36.01–42.19; CO: 37.37 mmol/L, 95% CI 33.88–40.86; p = 0.51) (Table 2). In the adjusted model the strongest effect was due to age (p = 0.007) and gender (p < 0.0001).

### Multivariate Regression and Correlation Analyses

We investigated determinants affecting bone turnover markers in T2DM by multivariate regression analysis (Table 3). Hereby only serum iPTH remained an independent determinant of lower serum bone turnover markers in T2DM. Intact PTH was positively associated with PINP (p = 0.02), BAP (p < 0.01) and CTX (p < 0.001). No significant association was found between serum bone turnover markers and other parameters such as age, BMI, HbA1c, serum sclerostin and diabetes disease duration. Magnesium was not an independent determinant for bone turnover markers in the multivariate regression analysis.

Additional analyses showed that lower serum iPTH correlated with lower PINP (r = 0.31, p = 0.001), CTX (r = 0.36, p < 0.001) and BAP (r = 0.26, p < 0.01) in patients with T2DM but not in non-diabetic controls (Table 4A and B).

### Table 1 Baseline characteristics in T2DM and non-diabetic controls (Co)

| Characteristics             | T2DM n = 110 | Co n = 92 |
|-----------------------------|--------------|-----------|
| Female, n (%)*              | 31 (28.2)    | 69 (75.0) |
| Age (years) ¥               | 63.7 ± 6.0   | 60.5 ± 6.3|
| Body mass index (kg/m²)¥    | 29.9 ± 4.3   | 24.9 ± 4.5|
| HbA1c (%)¥                 | 7.5 ± 1.2    | 5.5 ± 0.3 |
| Disease duration (years) ¥  | 13.5 (8, 20) | n/a       |
| Insulin treatment, n (%)    | 64 (58.2)    | n/a       |
| Metformin treatment, n (%)  | 94 (85.4)    | n/a       |
| GLP-1 treatment, n (%)      | 45 (40.9)    | n/a       |
| SGLT-2 treatment, n (%)     | 26 (23.6)    | n/a       |
| DPP-4 treatment, n (%)      | 26 (23.6)    | n/a       |
| Sulfonylurea treatment, n (%)| 11 (10.0)  | n/a       |
| Polynephropathy, n (%)      | 40 (36.4)    | n/a       |
| Retinopathy, n (%)          | 11 (10.0)    | n/a       |
| Nephropathy, n (%)          | 25 (22.7)    | n/a       |

*Values presented as mean ± SD or median (interquartile range, IQR)

* p-value < 0.001 for comparison between T2DM and non-diabetic controls

†defined as microalbuminuria

---

Fig. 1 Distribution of serum PINP and CTX levels in T2DM (n = 110) and non-diabetic controls (Co) (n = 88)
We also found a positive correlation between iPTH and magnesium in diabetes only (p = 0.03, Table 4A). In addition, we observed significantly lower iPTH levels in T2DM with magnesium levels ≤ 0.8 mmol/l (n = 55; median [IQR], 33.4 pg/ml [26.4 to 47.2]) as compared to patients with magnesium levels > 0.8 mmol/l (n = 53; 42.0 pg/ml [32.4 to 53.9]; p = 0.02). In non-diabetic controls serum iPTH were comparable in subjects with lower or higher magnesium levels.

There was no significant correlation between iPTH and HbA1c in T2DM.

**Discussion**

Within the present study we intended to assess potential determinants of low bone turnover in T2DM by evaluating the association between serum markers of bone resorption and formation with calciotropic hormones, serum sclerostin, glycaemic control and diabetes disease duration. Our results confirm that T2DM is associated with low bone turnover, as indicated by significantly lower levels of CTX and PINP compared to non-diabetic controls. We also found significantly lower serum iPTH levels in the diabetic group. In multivariate regression analyses low serum iPTH was shown to be an independent determinant of both bone resorption and bone formation parameters. No associations were found between serum bone turnover markers and glycaemic control, sclerostin levels or disease duration. Our results suggest that serum iPTH may be a regulator of low bone turnover in T2DM. Furthermore, patients with T2DM had significantly lower serum magnesium levels than controls and iPTH was positively correlated with serum magnesium in T2DM. We found significantly lower iPTH levels in diabetic patients with serum magnesium between 0.5 and 0.8 mmol/as compared to patients with normomagnesemia. We speculate that in the subset of T2DM patients with mild hypomagnesemia the observed relative hypoparathyroidism might be regulated by magnesium.

PTH promotes both bone formation and resorption via osteocyte signalling [33] by mechanisms which are not fully understood yet. Osteocytes are known to be crucial mediators of PTH action and play a central role in skeletal remodelling [33]. PTH reduces osteoblast apoptosis [34], inhibits adipocyte differentiation of early stem cells in the osteoblast lineage [35] and increases the number of skeletal progenitors [36].

Reyes-Garcia et al. found that decreased PTH levels in T2DM were associated with reduced serum levels of CTX and TRACP5b [22]. Dobnig et al. showed that decreased PTH levels and higher levels of glycaemia both independently contribute to lower bone turnover in elderly nursing home patients with T2DM [4]. Our patients with T2DM had significantly lower iPTH levels which were associated with lower levels of both PINP and CTX. Serum calcium and creatinine levels, 25 OH vitamin D and vitamin supplementation as well as calcium intake did not differ between the groups. We found significantly higher phosphate levels in T2DM compared to controls which may possibly be related to a relative hypoparathyroidism with
increased renal phosphate reabsorption in T2DM. 23.6% of diabetic patients were taking SGLT-2 inhibitors which have been reported to be associated with higher renal phosphate reabsorption but also, unlike in our study population, higher magnesium and iPTH levels and increased bone resorption [37]. Although the classical constellation of hypoparathyroidism with hypocalcemia was not present in patients with T2DM, iPTH levels were significantly lower and this relative hypoparathyroidism was found to be an independent determinant of low bone turnover in T2DM.

Amongst other mechanisms iPTH is supposed to down-regulate the SOST gene encoding for sclerostin which is an osteocyte-specific secreted WNT-inhibitor of bone formation [28, 38, 39]. Sclerostin levels increase with age and PTH was shown to be an independent determinant

### Table 2 Biochemical characteristics and dietary calcium and vitamin D intake in T2DM and non-diabetic controls (Co)

| Characteristics                             | T2DM |             |                | CO |             |                | p      |
|---------------------------------------------|------|-------------|----------------|----|-------------|----------------|--------|
|                                             | n    | Adjusted mean | 95% CI       | n  | Adjusted mean | 95% CI       |        |
| Fasting glucose (mmol/l)                    | 105  | 7.63        | 7.29, 7.96    | 90 | 5.57        | 5.20, 5.93    | <0.001 |
| PINP (ng/ml)                                | 110  | 39.61       | 35.37, 43.85  | 88 | 57.38       | 52.57, 62.18  | <0.001 |
| CTX (ng/ml)                                 | 110  | 0.29        | 0.26, 0.32    | 88 | 0.43        | 0.39, 0.46    | <0.001 |
| Bone-specific alkaline phosphatase (μg/l)  | 110  | 14.73       | 13.24, 16.23  | 88 | 16.45       | 14.75, 18.14  | 0.18   |
| Alkaline phosphatase (U/l)                  | 110  | 68.99       | 64.58, 73.41  | 89 | 67.19       | 62.22, 72.17  | 0.64   |
| Sclerostin (mmol/l)                         | 109  | 39.10       | 36.01, 42.19  | 88 | 37.37       | 33.88, 40.86  | 0.51   |
| Intact PTH (pg/ml)                          | 108  | 39.23       | 35.39, 43.07  | 88 | 46.47       | 42.17, 50.77  | 0.03   |
| 25OH vitamin D (nmol/l)                     | 110  | 59.00       | 53.60, 64.39  | 88 | 65.06       | 58.95, 71.18  | 0.19   |
| Calcium (mmol/l)                            | 110  | 2.36        | 2.23, 2.38    | 89 | 2.35        | 2.32, 2.37    | 0.64   |
| Phosphorus (mmol/l)                         | 110  | 1.24        | 1.21, 1.28    | 89 | 1.15        | 1.11, 1.19    | <0.001 |
| Magnesium (mmol/l)*                         | 110  | 0.81        | 0.79, 0.83    | 89 | 0.89        | 0.86, 0.92    | <0.001 |
| Sodium (mmol/l)                             | 110  | 137.74      | 136.96, 138.38| 89 | 138.51      | 137.63, 139.98| 0.24   |
| Creatinine (μg/l)                           | 110  | 73.99       | 69.79, 78.19  | 89 | 74.23       | 69.49, 78.97  | 0.95   |
| eGFR (ml/min)                               | 110  | 86.44       | 83.25, 89.63  | 89 | 85.84       | 82.25, 89.44  | 0.83   |
| U-albumin/creatinine ratio (mmol/mmol)      | 107  | 5.33        | 3.18, 7.48    | 86 | 1.89        | 0.56, 4.33    | 0.07   |
| Tmp/GFR** (mmol/l)                          | 108  | 1.12        | 1.09, 1.15    | 87 | 1.03        | 0.99, 1.06    | <0.001 |
| Dietary calcium intake (mg/d)               | 109  | 877         | 791, 963      | 92 | 954         | 859, 1049     | 0.29   |
| Vitamin D supplementation (IU/d)            | 30   | 1169        | 826–1512      | 34 | 926         | 566–1287      | 0.38   |

**all comparisons are adjusted for age, gender and BMI**

*additional adjustment for thiazide use and proton pump inhibitor use **renal tubular reabsorption of phosphate

Significant p-values <0.05 are highlighted in bold

### Table 3 Multivariate regression analysis in T2DM: Parameters determining serum bone turnover markers (PINP, CTX, BAP)

| Factors                  | Value | n   | Outcome          | Value | n   | Outcome          | Value | n   | Outcome          |
|--------------------------|-------|-----|------------------|-------|-----|------------------|-------|-----|------------------|
|                         |       |     | PINP (ng/ml)     |       |     | CTX (ng/ml)      |       |     | BAP (μg/L)       |
| Intercept                | –     | 101 | Estimate | SE  | p    | Estimate | SE  | p    | Estimate | SE  | p    |
| Age (years)              | 1 unit increase | 101 | −0.32  | 0.22 | 0.16  | −0.01  | 0.01 | 0.01  | −0.10  | 0.09 | 0.25 |
| BMI (kg/m²)              | 1 unit increase | 101 | 0.62   | 0.31 | 0.05  | 0.01   | 0.01 | 0.23  | 0.04   | 0.15 | 0.81 |
| Magnesium (mmol/l)       | 1 unit increase | 101 | 6.08   | 12.07 | 0.62  | 0.13   | 0.11 | 0.23  | −1.58  | 5.74 | 0.78 |
| Sclerostin (mmol/l)      | 1 unit increase | 101 | 0.13   | 0.07 | 0.08  | 0.01   | 0.01 | 0.78  | −0.06  | 0.04 | 0.09 |
| iPTH (pg/ml)             | 1 unit increase | 101 | 0.16   | 0.69 | 0.02  | 0.01   | 0.001| <0.001| 0.09   | 0.03 | <0.01|
| HbA1c (%)                | 1 unit increase | 101 | −0.89  | 1.11 | 0.43  | −0.14  | 0.18 | 0.18  | 1.05   | 0.53 | 0.05 |
| Disease duration (years) | 1 unit increase | 101 | 0.07   | 0.19 | 0.72  | −0.01  | 0.01 | 0.11  | −0.10  | 0.09 | 0.25 |
| Adjusted R2              |       | 101 | 0.10   | 0.14 | 0.08  |        |      |       |        |      |      |

**BIC** Bayesian information criterion, **AIC** Akaike information criterion, **SE** standard error

Significant p-values <0.05 are highlighted in bold
of sclerostin in patients without diabetes [29, 40, 41]. In type 1 diabetes (T1DM) and T2DM sclerostin levels were found to be higher compared to non-diabetic controls [10, 11, 29] which might be due to an impaired suppression of sclerostin production by PTH in patients with diabetes [29]. We hypothesized that the relative hypoparathyroidism in patients with T2DM might result in higher sclerostin levels, but in our cohort sclerostin levels were not significantly altered in T2DM. We could neither show a significant correlation between sclerostin and PTH levels nor between sclerostin and HbA1c. Although PTH is supposed to control sclerostin effects [42], it also uses other mechanisms to exert its influence on bone [33]. Our results suggest that specifically in T2DM other effects than those related to sclerostin might be responsible for low bone turnover.

The relative hypoparathyroidism described in T2DM has been linked to hyperglycaemia [4, 22, 30, 31], yet findings are inconsistent. Yamamoto et al. found low PTH levels in T2DM but did not identify any significant correlation between PTH and HbA1c. Although PTH is supposed to control sclerostin effects [42], it also uses other mechanisms to exert its influence on bone [33]. Our results suggest that specifically in T2DM other effects than those related to sclerostin might be responsible for low bone turnover.

Table 4 A) Correlation analyses for iPTH in T2DM

| Correlation of | With                | n   | Correlation coefficient | Type of correlation coefficient | p     |
|---------------|---------------------|-----|-------------------------|--------------------------------|-------|
| iPTH          | Retinopathy         | 108 | 0.06                    | Spearman’s                      | 0.54  |
|               | Neuropathy          | 108 | −0.14                   | Spearman’s                      | 0.14  |
|               | Nephropathy         | 108 | 0.03                    | Spearman’s                      | 0.78  |
|               | U-albumin/creatinine Ratio | 107 | −0.06                   | Pearson                         | 0.51  |
|               | HbA1c               | 108 | −0.01                   | Pearson                         | 0.95  |
|               | Disease Duration    | 108 | 0.15                    | Pearson                         | 0.12  |
|               | Magnesium           | 108 | 0.21                    | Pearson                         | 0.03  |
|               | PINP                | 108 | 0.31                    | Pearson                         | 0.001 |
|               | CTX                 | 108 | 0.36                    | Pearson                         | < 0.001 |
|               | BAP                 | 108 | 0.26                    | Pearson                         | < 0.01 |

Correlation of With
| n   | Correlation coefficient | Type of correlation coefficient | p     |
|-----|-------------------------|--------------------------------|-------|
| iPTH | Magnesium               | 88   | 0.12                   | Pearson | 0.26  |
| PINP | 87                      | 0.07                   | Pearson | 0.53  |
| CTX  | 87                      | 0.10                   | Pearson | 0.38  |
| BAP  | 87                      | −0.05                  | Pearson | 0.65  |

Significant p-levels < 0.05 are highlighted in bold

Medium and well-controlled with a mean HbA1c of 7.5% (± 1.2), whereas in the aforementioned studies [5, 21, 43] patients with diabetes had worse glycaemic control with an average HbA1c of at least 8.9% (± 2.5) [5].

As other possible mechanisms for an impaired PTH secretion in patients with T2DM a calcium-sensing defect and chronic hypomagnesemia [23] were previously described. We found significantly lower serum magnesium levels in our diabetic patients in comparison to non-diabetic controls which remained significant after correction for PPI and thiazide use. A substantial proportion (85.4%) of our diabetic patients were on metformin treatment which has been linked to hypomagnesemia in observational cohort studies [44]. However, a recent in vivo study showed that metformin treatment had no effect on magnesium homeostasis in diabetic mice which led to the conclusion that hypomagnesemia is a consequence of T2DM which is not modulated by metformin intake [45].

Interestingly, we saw a significant, albeit weak positive correlation between PTH and magnesium levels in T2DM which was not present in healthy controls.

PTH secretion by the parathyroid gland is physiologically controlled by serum calcium levels, but magnesium can exert similar effects. An increase in extracellular magnesium inhibits PTH secretion by activation of the calcium-sensing receptor [46]. Whilst low levels of magnesium are known to stimulate PTH secretion by activation of the calcium-sensing receptor, only severe hypomagnesemia with serum magnesium < 0.5 mmol/l and an intracellular magnesium deficit is supposed to induce a paradoxical block of PTH secretion [46, 47]. Accordingly, we
did not find any positive correlation between magnesium and PTH in our non-diabetic controls with normal magnesium and iPTH levels. An in vitro study demonstrated that rat parathyroid glands are sensitive to an inhibitory effect of magnesium only in the presence of a moderate to low calcium concentration [48]. We speculate that the lack of correlation between magnesium and iPTH in our controls may be related to a calcium level within the normal range.

In contrast, in T2DM, albeit calcium levels were not significantly different from the control group, iPTH levels were lower in patients with moderately low magnesium levels <0.8 mmol/l. We therefore speculate that unlike in the control group lower magnesium levels in T2DM might be associated with an impaired PTH secretion.

The prevalence of hypomagnesemia is increased in T2DM especially in patients with poor glycaemic control, with a longer disease duration and with chronic vascular complications [24, 25, 49]. It has been shown that the net tubular reabsorption of magnesium is decreased in diabetic patients in the presence of hyperglycaemia, leading to hypermagnesiuria and hypomagnesemia [50]. Furthermore, PTH in turn regulates magnesium homeostasis by modulating renal magnesium reabsorption through the distal convoluted tubule [23].

We speculate that the observed relative hypoparathyroidism in T2DM is mediated by lower magnesium levels in the subset of patients with mild hypomagnesemia. Hypoparathyroidism might also induce hypermagnesiuria which in turn could worsen the hypomagnesemic state in T2DM.

This study has particular limitations. First, the analyses are cross-sectional and can show only associations. Furthermore, our T2DM population was small and heterogenous, with more men in the diabetic group and more women in the control group. Although these differences were corrected for in the baseline characteristics, the small sample size and heterogeneity reduce the statistical power of this study. Furthermore, the mentioned results were significant but altogether weak, so that under consideration of the reduced statistical power they can only be used to generate hypotheses.

In conclusion, we confirm that T2DM is a state of low bone turnover. Low serum iPTH appears to be a regulator of low bone turnover in T2DM, whereas glycaemic control and disease duration seem not to be associated. Based on the relationship between serum levels of iPTH and magnesium, we hypothesize that in the cohort of T2DM with mild magnesium depletion low bone turnover may be linked to a hypomagnesaemia-related functional hypoparathyroidism. However, the mechanism underlying low iPTH in T2DM in general remains to be elucidated. Future investigations are required to (a) further explore the influence of relative hypoparathyroidism on bone turnover in T2DM and (b) to assess whether measurements of serum iPTH and magnesium are of clinical value in patients with type 2 diabetes.

Acknowledgements The present study was supported by the Swiss National Science Foundation (grant 320030_169407 to C.M.), a research grant from the Swiss Society for Endocrinology and Diabetology (SGED/SSED) and an unconditional research grant from Roche Diagnostics.

Author Contributions JV: data acquisition, analysis and interpretation, writing original draft LS: contributed equally to data acquisition, analysis and interpretation; revision of the manuscript, MT, AS, SB and AE contributed to the data acquisition. LG: statistical analysis of the data. BF, MK, CH: resources; CM: study conception, funding acquisition, methodology, resources, supervision, writing-review. All authors critically revised the manuscript and approved the final version. All authors agree to be accountable for the work and to ensure that any questions relating to the accuracy and integrity of the paper are investigated and properly resolved.

Funding Open access funding provided by University of Basel.

Declarations

Conflicts of interest Janina Vavanikunnel, Lilian Sewing, Maria Triantafyllidou, Anna Steighardt, Sandra Baumann, Andrea Egger, Leticia Grize, Barbara Felix, Marius Kraenzlin, Christoph Henzen, Christian Meier authors state that they have no conflicts of interest with respect to the submitted manuscript.

Human and Animal Rights and Informed Consent All investigations were performed according to the protocol approved by the Ethikkommission Nordwest- und Zentralschweiz EKNZ (reference number: EKNZ 2015-117).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Shu A, Yin M, Stein E et al (2012) Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int 23(2):635–641
2. Krakauer JC, Mckenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM (1995) Bone loss and bone turnover in diabetes. Diabetes 44(7):775–782
3. Manavalan J, Cremers S, Dempster D et al (2012) Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(9):3240–3250
4. Dobnig H, Pischeng-Sölken JC, Roth M et al (2006) Type 2 diabetes mellitus in nursing home patients: effects on bone

Springer
Determinants of Low Bone Turnover in Type 2 Diabetes—the Role of PTH

595
turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 91(9):3355–3363
5. Kanazawa I, Yamaguchi T, Yamamoto M et al (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94(1):45–49
6. Farr JD, Drake MT, Amin S, Melton LJ III, McCready LK, Khosla S (2014) In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29(4):787–795
7. Starup-Linde J, Vestergaard P (2016) Biochemical bone turnover markers in diabetes mellitus—a systematic review. Bone 82:69–78
8. Starup-Linde J, Eriksen S, Lykkeboe S, Handberg A, Vestergaard P (2014) Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int 25(6):1697–1708
9. Yamamoto M, Yamauchi M, Sugimoto T (2013) Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 98(10):4030–4037
10. Ardawi M-SM, Akhbar DH, AlShaikh A et al (2013) Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type 2 diabetes. Bone 56(2):355–362
11. Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL (2017) Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover—a systematic review and meta-analysis. Eur J Endocrinol 176(3):R137–R157
12. Gronvold A, Rimm EB, Willett WC, Andersen LB, Hu FB (2012) A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med 172(17):1306–1312. https://doi.org/10.1001/archinternmed.2012.3138
13. García-Martín A, Rozas-Moreno P, Reyes-García R et al (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97(1):234–241
14. Vestergaard P, Rejnmark L, Moskilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48(7):1292–1299
15. Bonds DE, Larson JC, Schwartz AV et al (2006) Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study. J Clin Endocrinol Metab 91(9):3404–3410. https://doi.org/10.1210/jc.2006-0614
16. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL (2017) Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 13(4):208–217
17. Schwartz AV, Hillier TA, Sellmeyer DE et al (2002) Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 25(10):1749–1754
18. Rabin MR, Patsch JM (2016) Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone research 4(1):1–9
19. Eller-Vainicher C, Cairoli E, Grassi G et al (2020) Pathophysicsiology and management of type 2 diabetes mellitus bone fragility. J Diabet Res. https://doi.org/10.1155/2020/7608964
20. Napoli N, Conte C, Eastell R et al (2020) Bone turnover markers do not predict fracture risk in type 2 diabetes. J Bone Miner Res 35(12):2363–2371
21. Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T (2012) Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 97(4):1277–1284
22. Reyes-García R, Rozas-Moreno P, López-Gallardo G et al (2013) Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol 50(1):47–52
23. McNair P, Christensen M, Madsbad S, Christiansen C, Transbol I (1981) Hypoparathyroidism in diabetes mellitus. Eur J Endocrinol 96(1):81–86
24. Kostov K (2019) Effects of magnesium deficiency on mechanisms of insulin resistance in Type 2 diabetes: focusing on the processes of insulin secretion and signaling. Int J Mol Sci 20(6):1351
25. Barbagallo M, Dominguez LJ (2015) Magnesium and type 2 diabetes. World J Diabetes 6(10):1152
26. Wittrant Y, Gorin Y, Woodruff K et al (2008) High d (+) glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42(6):1122–1130
27. Starup-Linde J, Lykkeboe S, Gregersen S et al (2016) Differences in biochemical bone markers by diabetes type and the impact of glucose. Bone 83:149–155
28. Adamis S (2009) Bone health in diabetes: considerations for clinical management. Curr Med Res Opin 25(5):1057–1072
29. Gennari L, Merlohti D, Valenti R et al (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97(5):1737–1744
30. D’Erasmo E, Pisani D, Ragno A, Raenetroph N, Vecchi E, Acca M (1999) Calcium homeostasis during oral glucose load in healthy women. Horm Metab Res 31(04):271–273
31. Thalassinos N, Hadijyann P, Tzanela M, Alevizaki C, Philokiprou D (1993) Calcium metabolism in diabetes mellitus: effect of improved blood glucose control. Diabet Med 10(4):341–344
32. Payne R (1998) Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem 35(2):201–206
33. Wein MN (2018) Parathyroid hormone signaling in osteocytes. JBone Miner Res 23(1):1–20
34. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolas-Sc (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Investig 104(4):439–446
35. Fan Y, Hanai J-i, Le PT et al (2017) Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab 25(3):661–672
36. Balani DH, Ono N, Kronenberg HM (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Investig 127(9):3327–3338
37. Nauka MA, Del Prato S, Meier JJ et al (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34(9):2015–2022
38. Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19(2):179
39. Brunow ME, Gardner JC, Van Ness J et al (2001) Bone dysplasia sclerostosis results from loss of the SOST gene product, a novel cystine knot–containing protein. American J Human Genet 68(3):577–589
40. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95(4):1991–1997
41. Ardawi MSM, Al-Kadi HA, Rouzi AA, Qari MH (2011) Determinants of serum sclerostin in healthy pre-and postmenopausal women. J Bone Miner Res 26(12):2812–2822
42. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37(2):148–158
43. Okazaki R, Totsuka Y, Hamano K et al (1997) Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 82(9):2915–2920
44. Kurihara S, de Baaij JH, Bouras H, Bindels RJ, Tack CJ, Hoenderop JG (2017) Determinants of hypomagnesemia in patients with type 2 diabetes mellitus. Eur J Endocrinol 176(1):11–19
45. Kurstjens S, Bouras H, Overmars-Bos C et al (2019) Diabetes-induced hypomagnesemia is not modulated by metformin treatment in mice. Sci Rep 9(1):1–9
46. Vetter T, Lohse MJ (2002) Magnesium and the parathyroid. Curr Opin Nephrol Hypertens 11(4):403–410
47. Brandi ML, Bilezikian JP, Shoback D et al (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101(6):2273–2283
48. Rodríguez-Ortiz ME, Canalejo A, Herencia C et al (2014) Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant 29(2):282–289
49. Mather H, Nisbet JA, Burton G et al (1979) Hypomagnesaemia in diabetes. Clin Chim Acta 95(2):235–242
50. McNAIR P, Christensen MS, Christiansen C, Madsbad S, Transbøl I (1982) Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. European J Clin Investig 12(1):81–85

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.